Affiliation:
1. Junior resident(MOTR), Department of Ophthalmology,RG Kar Medical College and Hospital
2. Associate Professor, Department of Ophthalmology, RG Kar Medical College and Hospital.
3. Junior resident, Department of Ophthalmology,RG Kar Medical College and Hospital.
Abstract
BACKGROUND:India accounts highest burden of tuberculosis cases about 2.64millions with incidence of 193 in year
2019(WHO). India is among the largest countries to implement National Tuberculosis Elimination Program(previously
known as RNTCP). This program provides now daily regimen to the patients,where patients have to take daily dosage of ethambutol according
to the body weight category of patients along with others ATDs ,which is a cause of concern,particular with regard to the ocular toxicity of
ethambutol.The present study was undertaken to explore the ocular toxicity in the newly diagnosed cases of tuberculosis patients registered
under the program in terms of visual acuity,color vision,optic disc ndings,visual eld and IOP changes. :EarlyAIMS AND OBJECTIVES
detection of ocular changes due to ethambutol toxicity and early stoppage of ethambutol from the further ocular damages. STUDY
DESIGNS:Hospital based prospective observational study for approximately one year(April 2020 to March 2021) in a tertiary health care centre
in Kolkata. Both eyes of 53 newly diagnosed tuberculosis patients were examined prior to start ATDs(including ethambutol),fourMETHODS:
and eight weeks after initiation phases and anytime within eight weeks in case of sudden onset of ocular complaints.Visual acuity,color
vision,optic disc ndings,eld of vision,IOP were noted,tabulated and analyzed. Out of 106 eyes in 53 patients, decrease in visualRESULTS:
acuity was seen in 10eyes(9.43%) ,impairment in red-green color in 12eyes(11.32%),optic disc abnormalities in 6eyes(5.66%) and visual eld
changes were seen in 8eyes(7.55%).The defects were bilateral in all cases.There were no signicant changes in IOP within 8weeks
commencement of ethambutol therapy.The patients with ocular changes were advised to stop ethambutol and showed signicant improvement
in vision on follow up later. In our study populations of 53 patients, 6patients (11.32%)were found with ocular changes due toCONCLUSION:
ethambutol toxicity. So early detection of ocular changes due to ethambutol toxicity has great importance for its prevention.So baseline
ophthalmological examination prior to start ethambutol and periodic follow up can prevent untoward irreversible vision loss due to ethambutol
toxicity.
Reference16 articles.
1. Place VA, Black H. New antituberculous agents: Laboratory and clinical studies. Ann N Y Acad Sci. 1966;135:681–709.
2. Inocencio FP, Castillo TR. Toxic optic neuropathy secondary to ethambutol. Philipp JOphthalmol. 1999;24:65–8.
3. World Health Organization. Ethambutol efficacy and toxicity: Literature review and recommendations for daily and intermittent dosage in children. Geneva: World Health Organization;
4. Adel A. Ophthalmological side-effects of ethambutol. Scand J Respir Dis Suppl. 1969;69:55–8.
5. Schild HS, Fox BC. Rapid-onset reversible ocular toxicity from ethambutol therapy. Am J Med. 1991;90:404–6.